CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 41 enrolled
Drug / intervention
Umooze +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02313233
NCT02313233N/ACompleted
CompareCT.gov

Research on Benefit of Umooze as Add-on Therapy in Benign Prostatic Hyperplasia

Golden Biotechnology Corporation·interventional·Posted Dec 10, 2014·Updated Jun 21, 2016

In Brief

A clinical study evaluating Umooze and Placebo for Benign Prostatic Hyperplasia. Completed, enrolled 41 participants across 1 site.

Detailed Summary

To evaluate the improvement in symptoms of Benign Prostatic Hyperplasia (BPH) according to the Prostate Symptom Score (IPSS) and Quality- of- Life (QoL) index after add- on therapy of Umooze twice daily administration for 56 days in patients with BPH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 10, 2014
Enrollment StartDec 1, 2013
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.6 years ago

Interventions

Umoozedietary

Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.

Placebodietary

Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.